Back to News
Market Impact: 0.2
OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial
Source: Nasdaq
Healthcare & Biotech
OSE Immunotherapeutics announced topline results from the academic, international Phase 2 Combi-TED trial evaluating Tedopi (OSE2101) with chemotherapy or an anti-P... treatment. The supplied article text is truncated before reporting the results, so the trial outcome and any associated figures are not available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
OSE0.00
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template